Xylem affirms Q3 adjusted EPS and sales guidance ranges
Xylem (NYSE: XYL) affirms Q3 adjusted EPS guidance of $1.42-$1.47 versus a $1.46 analyst estimate and maintains Q3 sales outlook at $2.300 billion versus $2.316 billion expected.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.